Changing the Status Quo: Four Landmark Studies and their Implication for Melanoma Treatment
The crown jewel of the Melanoma Research Alliance has always been—and will always be—good science. Through science, we not only gain a better understanding of melanoma, but the ability to translate that understanding into better treatments, which in turn lead to a better quality of life for people with melanoma. At MRA, solid scientific leadership is at the forefront of everything we do. That’s why the MRA Board of Directors was thrilled to hear a presentation by fellow Board member and world-class researcher, Dr. Suzanne Topalian, on four landmark studies and their implications for melanoma treatment.
A Mother’s Perspective: New Options for Pediatric Melanoma
When Cheryl Trocke’s nine-year old son Graham was diagnosed with melanoma four years ago, she quickly learned that when it comes to kids, there were no great treatment options and that care can vary greatly based on where your child is treated. After surgically removing the primary tumor, Graham’s doctors suggested a treatment plan of ‘wait and see.’
Non-invasive Detection Modalities and Metastatic Risk Stratification for Melanoma: Where Are We Now?
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 10 July 2017 In Prevention, Science, Treatment
While dermatologists have advocated for patient education about irregular skin lesions in order to catch melanomas earlier, dermatologists ultimately play the largest role in the detection and excision of abnormal skin lesions via skin biopsy. However, visual recognition and assessment of pigmented skin lesions is limited to the eye of the dermatologist, and can be challenging for even the most experienced clinicians.
Trena's Story: An African-American Retiree's Journey with Melanoma
8 June 2016 In Melanoma Stories
“Trena, you have melanoma and you are going to lose your toe. “ WHAT?!?! I am a Black woman in her sixties—that is crazy!!
Research Q&A: Dr. Tim Bullock
21 March 2016 In Science
In the latest blog post, we chatted with the University of Virginia’s Tim Bullock, Ph.D., a tumor immunologist in the Pathology Department and MRA-funded investigator. Read on to learn what he has to say about melanoma research and prevention efforts.